RxDoctor Payments Data

Todd Bishop, DO

Pulmonary Disease · Middletown, CTNPI 1497750152

Payments from drug & device makers

$332in general payments, 2019–2025

Across 13 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$82
  • GSK$58
  • Covidien LP$52
  • Insmed, Inc.$29
  • CSL Behring$28
  • Vapotherm Inc$26
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$32097%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dexcom, Inc.1$82
GSK4$58
Covidien LP2$52
Insmed, Inc.1$29
CSL Behring1$28
Vapotherm Inc1$26
Merck1$25
Sanofi1$21
AstraZeneca1$12

How this compares

$332 in reported general payments places this provider in the 30th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$58,263
Medicare patients
195
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$50,624
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr42$43,820
Spiriva HandihalerTiotropium Bromide34$32,396
Combivent RespimatIpratropium/Albuterol Sulfate26$18,311
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$10,987
SymbicortBudesonide/Formoterol Fumarate23$9,051
Fluticasone Propionate HfaFluticasone Propionate21$6,886
Advair DiskusFluticasone Propion/Salmeterol14$5,865
Ventolin HfaAlbuterol Sulfate23$2,646
Albuterol Sulfate HfaAlbuterol Sulfate64$2,127
Azithromycin11$299
Montelukast Sodium45$265
Azelastine Hcl12$220
Gabapentin14$163
Prednisone64$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$58$94,44488 claims
AstraZenecaSymbicort$12$9,05123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →